Abstract
Management of diabetes in the elderly population
The age over 65 is usually seen as the limit above which it is difficult to determine an optimal treatment strategy due to the absence or a limited number of studies concerning the respective population. The Polish Diabetes Association encourages that therapy in this particular group of patients be customized to individual needs due to numerous comorbidities and a different – as compared to the general population - benefit-to-risk ratio (in terms of safety). However, it is always necessary to take into account the patient's chronological and biological age (including the presence of chronic complications of diabetes), which ultimately impacts therapeutic decisions.
Piśmiennictwo
1. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2019. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetologia Praktyczna 2019;5(1):1-99
2. Haw J, Galaviz K, Straus A, et al. Long-term sustainability of diabetes prevention approaches: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med 2017;177(12):1808-17
3. Lean M, Leslie W, Barnes A, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomized trial. Lancet 2018;391(10120):541-51
4. Lean M, Leslie W, Barnes A, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol 2019;7(5):344-55
5. Williamson J, Supiano M, Applegate W, et al. SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA 2016;315:2673-82
6. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 – Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens 2017;35:922-44
7. Wijkman M, Lanne T, Engvall J, et al. Masked nocturnal hypertension–a novel marker of risk in type 2 diabetes. Diabetologia 2009;52:1258-64
8. Messerli F, Mancia G, Conti C, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006;144(12):884-93
9. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal 2018;39:3021-104